Time to look further into the future
We raise Revenio Group's target price to 38.00 euros (formerly 37.00 euros) and keep the accumulate recommendation of the share at the former level. Revenio seems to be making steady progress in projects in which they are building prerequisites for continuing growth, and the company has the prerequisites to increase investments. The valuation multiples of Revenio's share are on the high side, but owing to the stable prospects for revenue growth and good predictability of the result we see some upside.
Revenio Group
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
Read more on company pageKey Estimate Figures16.02.2018
2017 | 18e | 19e | |
---|---|---|---|
Revenue | 26.8 | 31.1 | 37.0 |
growth-% | 14.33 % | 16.05 % | 19.00 % |
EBIT (adj.) | 9.5 | 12.3 | 15.5 |
EBIT-% (adj.) | 35.52 % | 39.62 % | 41.97 % |
EPS (adj.) | 0.90 | 1.23 | 1.54 |
Dividend | 0.78 | 1.00 | 1.20 |
Dividend % | 6.50 % | 3.79 % | 4.54 % |
P/E (adj.) | 13.40 | 21.42 | 17.21 |
EV/EBITDA | 8.61 | 15.51 | 11.95 |